Physician profile
Arghavan Almony
NPI 1558465278
$86,907.10
in general payments reported to CMS, 2019-2025
22 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $1,916 · 2021: $719 · 2022: $1,340 · 2023: $33K · 2024: $31K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Consulting Fee: $12K · Travel and Lodging: $7,882 · Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,480.00 |
| Consulting Fee | $11,865.00 |
| Travel and Lodging | $7,882.36 |
| Food and Beverage | $4,050.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $82,059.64 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $547.20 | 2020-2025 | Eylea Hd |
| Biotissue Holdings INC. | $544.20 | 2020-2025 | |
| Notal Vision, INC. | $458.80 | 2022 | |
| Apellis Pharmaceuticals, INC. | $375.19 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $370.77 | 2024-2025 | Clareon, Unity, Centurion |
| Novartis Pharmaceuticals Corporation | $253.30 | 2019-2020 | |
| Genentech, INC. | $246.57 | 2019-2021 | |
| Abbvie INC. | $95.94 | 2024-2025 | |
| Astellas Pharma US INC | $60.24 | 2024-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $49.89 | 2020-2021 | |
| Biogen, INC. | $39.78 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $34.18 | 2022 | |
| Carl Zeiss Meditec, INC. | $31.44 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $30.57 | 2025 | Idosetr |
| Coherus Oncology, INC. | $29.40 | 2023 | |
| Mallinckrodt Hospital Products INC. | $25.68 | 2023 | Acthar |
| Shire North American Group INC | $24.69 | 2019 | |
| Maculogix, INC. | $19.56 | 2019 | |
| Allergan, INC. | $18.51 | 2021 | |
| Alimera Sciences, INC. | $16.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arghavan Almony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.